Active, Not Recruiting
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
NCT03422393
- Conditions
- Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +16 more
- Locations
-
- UC San Diego Moores Cancer Center La Jolla, California, United States